The NeurologyLive® multiple sclerosis (MS) clinical focus page offers information, podcasts, videos, and news about the latest study and clinical trial findings, FDA actions, clinical guideline updates, and expert interviews related to the care and management of patients with MS, including relapsing MS and progressive MS, as well as related and demyelinating disorders such as neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein antibody-associated disease.
May 19th 2024
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Huntington disease.
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
September 15, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
CogEx Trial Questions Efficacy of Cognitive Rehabilitation and Exercise for Progressive MS
November 20th 2023A recent study conducted across 11 centers globally challenged the assumption that cognitive rehabilitation and exercise synergistically benefit patients with progressive multiple sclerosis.
Effects of Long-term CPAP Therapy in Multiple Sclerosis: Daria Trojan, MD, MSc
November 15th 2023The associate professor in the department of neurology and neurosurgery at McGill University discussed results from a study on the long-term use of continuous positive airway pressure treatment among patients with multiple sclerosis and sleep apnea presented at MSMilan 2023. [WATCH TIME: 5 minutes]
IL-6 Inhibitor Tocilizumab Effective in Treating NMOSD, Meta-Analysis Suggests
November 15th 2023A recent meta-analysis on tocilizumab in neuromyelitis optica spectrum disorder (NMOSD) emphasized its effectiveness in reducing relapse rates and improving patient function, with patient-specific factors influencing outcomes.
Phase II Clinical Trial: Fenebrutinib
Amit Bar-Or, MD, FRCPC, summarizes fenebrutinib phase II results for the treatment of multiple sclerosis.
Phase II Clinical Trial: Evobrutinib
Patrick Vermersch, MD, PhD, summarizes phase II clinical trial of evobrutinib for the treatment of multiple sclerosis.
Cognitive Benefits in Multiple Sclerosis Seen Through Transcranial Current Stimulation
November 10th 2023Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.
ATA188 Fails to Meet Primary End Point In Phase 2 EMBOLD Study of Progressive MS
November 9th 2023The phase 2 EMBOLD study on ATA188, an allogenic T-cell immunotherapy for non-active progressive multiple sclerosis, did not meet its primary endpoint of confirmed disability improvement after 12 months of treatment.
Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening
November 9th 2023The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Impact of Fatigue Overlooked in Disease-Modifying Therapy Trials for Multiple Sclerosis
November 9th 2023A recent systematic review identified that only 5% of disease-modifying therapy trials for patients with multiple sclerosis assessed fatigue as an outcome, with only 28% among 7 trials showing statistically significant results in the measurement.
BTK Inhibitor Clinical Development
Patrick Vermersch, MD, PhD, and Krzysztof Selmaj, MD, PhD, provide an overview of the BTKi that are currently under investigation for MS, and Gavin Giovannoni, MBBCh, PhD, FCP, FRCP, FRCPath, discusses what in vivo and in vitro preclinical work in models of MS have shown.
Amit Bar-Or, MD, FRCPC, provides an overview of the history of BTKi’s as well as what makes this class of drug a promising target for relapsing and remitting forms of MS.